Analysts predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post $28.96 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The lowest sales estimate is $27.50 million and the highest is $31.36 million. BioDelivery Sciences International posted sales of $14.16 million in the same quarter last year, which indicates a positive year-over-year growth rate of 104.5%. The business is expected to report its next earnings results on Thursday, November 14th.

On average, analysts expect that BioDelivery Sciences International will report full-year sales of $108.81 million for the current fiscal year, with estimates ranging from $105.10 million to $113.50 million. For the next year, analysts forecast that the business will report sales of $153.27 million, with estimates ranging from $139.90 million to $177.39 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 0.85%. The business had revenue of $29.68 million for the quarter, compared to analysts’ expectations of $25.30 million.

Several brokerages have recently commented on BDSI. BidaskClub raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating in a research report on Friday. William Blair reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. Finally, ValuEngine cut shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $6.20.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $3.82, for a total value of $30,560.00. Following the transaction, the director now owns 596,754 shares of the company’s stock, valued at $2,279,600.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Sirgo sold 157,177 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $4.79, for a total transaction of $752,877.83. Following the completion of the transaction, the director now directly owns 1,874,637 shares in the company, valued at approximately $8,979,511.23. The disclosure for this sale can be found here. Insiders have sold 340,864 shares of company stock worth $1,648,479 in the last ninety days. Corporate insiders own 8.94% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of BDSI. BTR Capital Management Inc. bought a new position in BioDelivery Sciences International in the second quarter worth about $47,000. Cutter & CO Brokerage Inc. bought a new position in BioDelivery Sciences International in the second quarter worth about $60,000. Weiss Asset Management LP bought a new position in BioDelivery Sciences International in the first quarter worth about $113,000. Nisa Investment Advisors LLC bought a new position in BioDelivery Sciences International in the third quarter worth about $148,000. Finally, Resources Investment Advisors LLC. bought a new position in BioDelivery Sciences International in the second quarter worth about $172,000. 68.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BDSI stock traded up $0.01 during trading hours on Monday, hitting $5.16. 757,150 shares of the company were exchanged, compared to its average volume of 729,868. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.09 and a current ratio of 2.34. BioDelivery Sciences International has a one year low of $2.80 and a one year high of $5.37. The business’s 50-day simple moving average is $4.61 and its two-hundred day simple moving average is $4.49. The stock has a market capitalization of $461.04 million, a price-to-earnings ratio of -7.07 and a beta of 0.33.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.